Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

ORGO
Organogenesis Holdings Inc. Class A Common Stock
stock NASDAQ

At Close
Oct 23, 2025 3:59:58 PM EDT
4.10USD+0.737%(+0.03)518,972
0.00Bid   0.00Ask   0.00Spread
Pre-market
Oct 21, 2025 9:13:30 AM EDT
4.10USD+0.737%(+0.03)0
After-hours
0.00USD0.000%(0.00)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
06:20PM EST  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Jan 29, 2022
11:05PM EST  Organogenesis Holdings Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm   PR Newswire
Jan 23, 2022
12:43PM EST  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Jan 20, 2022
10:55PM EST  CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Organogenesis   PR Newswire
Jan 17, 2022
11:07AM EST  Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP   GlobeNewswire Inc
Jan 13, 2022
12:49PM EST  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Jan 12, 2022
09:50AM EST  8, 2022 Deadline in Securities Fraud Class Action Lawsuit against Organogenesis Holdings Inc.   PR Newswire
Jan 9, 2022
04:36PM EST  Kessler Topaz Meltzer & Check, LLP: Reminds Investors of Deadline   GlobeNewswire Inc
Jan 8, 2022
01:01PM EST  Hagens Berman urges Organogenesis Holdings Inc. (NASDAQ: ORGO) investors with significant losses to submit your losses now.   GlobeNewswire Inc
Jan 4, 2022
04:07PM EST  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Jan 3, 2022
07:20PM EST  February 8, 2022 Deadline in Securities Fraud Class Action Lawsuit Filed Against Organogenesis Holdings, Inc.   PR Newswire
02:22PM EST  Hagens Berman urges Organogenesis Holdings Inc. (NASDAQ: ORGO) investors with significant losses to submit your losses now.   GlobeNewswire Inc
Jan 1, 2022
05:11PM EST  Investor Deadline Alert: Kessler Topaz Meltzer & Check, LLP   GlobeNewswire Inc
Dec 29, 2021
03:12PM EST  LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors With   PR Newswire
Dec 28, 2021
09:59AM EST  Hagens Berman urges Organogenesis Holdings Inc. (NASDAQ: ORGO) investors with significant losses to submit your losses now.   GlobeNewswire Inc
Dec 25, 2021
08:10PM EST  Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class   PR Newswire
Dec 24, 2021
10:11AM EST  Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud   GlobeNewswire Inc
Dec 23, 2021
10:10AM EST  Hagens Berman urges Organogenesis Holdings Inc. (NASDAQ: ORGO) investors with significant losses to submit your losses now.   GlobeNewswire Inc
Dec 16, 2021
08:50AM EST  Securities Fraud Class Action Lawsuit Filed Against Organogenesis Holdings Inc. (ORGO)   PR Newswire
Dec 15, 2021
03:37PM EST  Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud   GlobeNewswire Inc
12:38PM EST  Gainey McKenna & Egleston Announces A ClassAction   GlobeNewswire Inc
Dec 14, 2021
10:16AM EST  Organogenesis Holdings (ORGO) Investors with Substantial Losses to Contact Firm's Attorneys Now, Securities Fraud Class Action Filed   PR Newswire
Dec 12, 2021
09:00PM EST  ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating   GlobeNewswire Inc
Dec 10, 2021
10:07PM EST  Pomerantz Law Firm Announces the Filing of a Class Action Against   GlobeNewswire Inc
Dec 7, 2021
09:00PM EST  ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating   GlobeNewswire Inc
Dec 5, 2021
08:36AM EST  Investigation Alert: Did You Lose Money on Your Investment? Johnson Fistel, LLP   PR Newswire
Dec 2, 2021
09:00PM EST  ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating   GlobeNewswire Inc
Nov 22, 2021
07:12AM EST  Organogenesis Appoints Prathyusha Duraibabu To Board   RTTNews
07:00AM EST  Organogenesis Appoints Prathyusha Duraibabu to Board of Directors   GlobeNewswire Inc
Nov 20, 2021
10:55AM EST  Investigation Alert: Did You Lose Money on Your Investment? Johnson Fistel, LLP   PR Newswire
Nov 10, 2021
08:43AM EST  SVB Leerink Maintains Outperform on Organogenesis Holdings, Lowers Price Target to $20   Benzinga
Nov 9, 2021
04:56PM EST  Organogenesis Holdings Q3 EPS $0.09 Beats $0.06 Estimate, Sales $113.80M Beat $112.67M Estimate   Benzinga
11:42AM EST  The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data   Benzinga
11:25AM EST  Earnings Scheduled For November 9, 2021   Benzinga
Nov 8, 2021
07:30AM EST  Organogenesis Holdings Inc. to Participate in the Credit Suisse   GlobeNewswire Inc
Nov 1, 2021
04:30PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. (Organogenesis or the Company) (NASDAQ:ORGO). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
09:39AM EDT  Hagens Berman urges Organogenesis Holdings Inc. (NASDAQ: ORGO) investors with significant losses to submit your losses now.   GlobeNewswire Inc
Oct 27, 2021
09:25AM EDT  Organogenesis Showcases Latest Advanced Wound Care Innovations and   GlobeNewswire Inc
Oct 25, 2021
06:12PM EDT  Hagens Berman urges Organogenesis Holdings Inc. (NASDAQ: ORGO) investors with significant losses to submit your losses now.   GlobeNewswire Inc
Oct 21, 2021
09:30AM EDT  (ORGO) Investors with Significant Losses to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations   PR Newswire
Oct 20, 2021
02:52PM EDT  Hagens Berman urges Organogenesis Holdings Inc. (NASDAQ: ORGO) investors with significant losses to submit your losses now.   GlobeNewswire Inc
Oct 13, 2021
01:54PM EDT  Organogenesis Holdings Option Alert: Nov 19 $10 Calls Sweep (10) near the Ask: 258 @ $2.35 vs 111 OI; Earnings 11/9 After Close Ref=$10.8   Benzinga
Oct 12, 2021
03:09PM EDT  Mid-Afternoon Market Update: R. R. Donnelley & Sons Surges Following Buyout Offer; Columbia Banking System Shares Slide   Benzinga
01:21PM EDT  Mid-Day Market Update: Dow Falls 60 Points; Nutriband Shares Spike Higher   Benzinga
11:49AM EDT  Mid-Morning Market Update: Markets Edge Higher; Fastenal Reports In-Line Earnings   Benzinga
Oct 7, 2021
04:05PM EDT  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that third quarter of fiscal year 2021 financial results will be reported after the market closes on Tuesday, November 9th.   GlobeNewswire Inc
Sep 17, 2021
10:39AM EDT  Organogenesis Holdings Earnings Perspective: Return On Capital Employed   Benzinga
Sep 10, 2021
09:00AM EDT  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the following upcoming investor conferences:   GlobeNewswire Inc
Aug 23, 2021
07:05AM EDT  Net Health Teams With Organogenesis For More Efficient Insurance Benefits Verification   RTTNews
07:01AM EDT  Net Health Partners with Organogenesis for More Efficient Insurance Benefits   PR Newswire
Aug 10, 2021
05:32PM EDT  Organogenesis Q2 Earnings Beat Expectations; Sales Jump 79%; Raises FY21 Sales Outlook   Benzinga
08:37AM EDT  Credit Suisse Maintains Outperform on Organogenesis Holdings, Raises Price Target to $25   Benzinga
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 9, 2021
04:39PM EDT  Organogenesis Holdings: Q2 Earnings Insights   Benzinga
04:05PM EDT  Organogenesis Sees FY21 Revs $456M-$472M Vs $446.28M Est   Benzinga
04:04PM EDT  Organogenesis Holdings Q2 EPS $0.15 Beats $0.07 Estimate, Sales $123.20M Beat $107.30M Estimate   Benzinga
04:03PM EDT  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the three and six months ended June 30, 2021.   GlobeNewswire Inc
04:01PM EDT  Organogenesis Holdings Inc. Announces New $200 Million Credit   GlobeNewswire Inc
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
04:11AM EDT  Earnings Scheduled For August 9, 2021   Benzinga
Aug 8, 2021
10:11AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Jul 2, 2021
07:30AM EDT  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2021 financial results will be reported after the market closes on Monday, August 9th.   GlobeNewswire Inc
Jun 30, 2021
09:39AM EDT  Organogenesis Holdings Option Alert: Oct 15 $12.5 Calls Sweep (7) near the Ask: 319 @ $5.0 vs 435 OI; Earnings 8/9 After Close [est] Ref=$16.57   Benzinga
Jun 24, 2021
09:51AM EDT  Organogenesis Holdings Insights: Return On Capital Employed   Benzinga
Jun 8, 2021
11:38AM EDT  Looking Into Organogenesis Holdings's Return On Capital Employed   Benzinga
May 27, 2021
09:46AM EDT  Shares of Organogenesis Holdings Inc. (ORGO) are currently trading at $18.80, up $2.17 or 13.05%, with trading volume of over 689K versus an average volume of 781K shares. The stock has been trading in the range of $3.23 - $24.34 for the past one year.   RTTNews
May 26, 2021
05:51PM EDT  Crocs Set to Join S&P MidCap 400 and Organogenesis to Join S&P SmallCap 600   PR Newswire
05:18PM EDT  Organogenesis To Join S&P Smallcap 600   Benzinga
May 11, 2021
09:04AM EDT  SVB Leerink Maintains Outperform on Organogenesis Holdings, Lowers Price Target to $26   Benzinga
May 10, 2021
05:13PM EDT  In a release issued under the same headline earlier today byOrganogenesis Holdings Inc. (Nasdaq: ORGO), please note that in the third bullet of theFirst Quarter 2021 Financial Results Summary, thenet revenue from the sale of non-PuraPly products was $61.2 million, not $32.0 million.The corrected release follows:   GlobeNewswire Inc
05:09PM EDT  Organogenesis Holdings: Q1 Earnings Insights   Benzinga
05:02PM EDT  Organogenesis Holdings Q1 EPS $0.07 Beats $(0.02) Estimate, Sales $102.55M Beat $87.57M Estimate   Benzinga
04:28PM EDT  Organogenesis Sees FY21 Sales Guidance Of $438M-$454M Vs $397.24M Estimates   Benzinga
04:28PM EDT  Organogenesis Holdings Q1 EPS $0.07 Beats $(0.02) Estimate, Sales $102.60M Beat $87.57M Estimate   Benzinga
04:05PM EDT  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the three months ended March 31, 2021.   GlobeNewswire Inc
07:30AM EDT  Organogenesis Appoints Jon Giacomin to Board of Directors   GlobeNewswire Inc
04:09AM EDT  Earnings Scheduled For May 10, 2021   Benzinga
May 7, 2021
10:08AM EDT  Earnings Outlook for Organogenesis Holdings   Benzinga
Apr 12, 2021
07:30AM EDT  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2021 financial results will be reported after the market closes on Monday, May 10.   GlobeNewswire Inc
Mar 31, 2021
09:11AM EDT  The stock, Organogenesis Holdings Inc. (ORGO), featured on our 'Small Stocks - Big Potential' section on October 15, 2020, at an opening price of $4.40. On March 23, 2021, the stock touched a new 52-week high of $21.75, representing a gain of 394.3% from our published price. ORGO closed yesterday's trade at $18.17, down 29 cents or 1.57%.   RTTNews
Mar 24, 2021
08:59AM EDT  The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping   Benzinga
Mar 23, 2021
08:18AM EDT  The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO   Benzinga
01:31AM EDT  AZN's COVID-19 Jab Shows 79% Efficacy, ZEAL Wins FDA   RTTNews
Mar 18, 2021
08:16AM EDT  The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq   Benzinga
Mar 17, 2021
07:42AM EDT  10 Biggest Price Target Changes For Wednesday   Benzinga
07:27AM EDT  SVB Leerink Maintains Outperform on Organogenesis Holdings, Raises Price Target to $22   Benzinga
Mar 16, 2021
04:41PM EDT  Recap: Organogenesis Holdings Q4 Earnings   Benzinga
04:13PM EDT  Organogenesis Sees FY21 Sales $390M-$405M Which Is An Increase By 15%-20% From Last Year   Benzinga
04:11PM EDT  Organogenesis Holdings Q4 EPS $0.15 Beats $0.13 Estimate, Sales $106.80M Beat $99.18M Estimate   Benzinga
04:05PM EDT  Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year   GlobeNewswire Inc
08:17AM EDT  The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study   Benzinga
04:46AM EDT  Earnings Scheduled For March 16, 2021   Benzinga
Mar 14, 2021
08:14AM EDT  Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations   Benzinga
Mar 3, 2021
07:46AM EST  The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study   Benzinga
Mar 2, 2021
08:01AM EST  The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data   Benzinga
Feb 26, 2021
08:17AM EST  The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida   Benzinga
Feb 16, 2021
07:09AM EST  Organogenesis Appoints David C. Francisco As Chief Financial Officer   Benzinga
Feb 10, 2021
07:34AM EST  The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs   Benzinga
Feb 9, 2021
04:05PM EST  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the following upcoming investor conferences:   GlobeNewswire Inc
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Feb 8, 2021
04:05PM EST  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that fourth quarter and fiscal year 2020 financial results will be reported after the market closes on Tuesday, March 16.   GlobeNewswire Inc
Feb 5, 2021
07:44AM EST  The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street   Benzinga
Feb 4, 2021
07:22AM EST  The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs   Benzinga
Feb 3, 2021
07:31AM EST  The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision   Benzinga
Feb 2, 2021
08:05AM EST  The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment   Benzinga
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 20, 2021
06:26AM EST  SVB Leerink Maintains Outperform on Organogenesis Holdings, Raises Price Target to $13   Benzinga
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 14, 2021
07:57AM EST  The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates   Benzinga
07:06AM EST  Organogenesis Says First Patient Enrolled In Pivotal Phase 3 Clinical Trial On ReNu   RTTNews
07:05AM EST  Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu for Knee Osteoarthritis   Benzinga
07:00AM EST  Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical   GlobeNewswire Inc
Jan 13, 2021
04:07PM EST  Organogenesis Sees Q4 Preliminary Sales Results $104.6M-$106M Vs $74.6M YoY, FY20 Sales $336.1M-$337.5M Vs $261M YoY   Benzinga
04:05PM EST  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported preliminary financial results for the three months and twelve months ended December 31, 2020.   GlobeNewswire Inc
Jan 11, 2021
09:03AM EST  Organogenesis ReNu Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis Of The Knee   Benzinga
09:02AM EST  FDA Determines ReNu Preliminary Clinical Evidence Indicates Potential to Address Unmet Medical Needs for the Management of Symptoms Associated with Knee Osteoarthritis   GlobeNewswire Inc
Jan 7, 2021
09:26AM EST  Credit Suisse Maintains Outperform on Organogenesis Holdings, Raises Price Target to $9   Benzinga
Jan 6, 2021
07:31AM EST  The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping   Benzinga
Jan 5, 2021
04:05PM EST  Organogenesis Holdings Inc. to Participate in the ICR Conference 2021   GlobeNewswire Inc
08:39AM EST  The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data   Benzinga
Dec 30, 2020
08:16AM EST  The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data   Benzinga
Dec 29, 2020
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 18, 2020
07:48AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data   Benzinga
07:45AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data   Benzinga
Dec 8, 2020
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Nov 24, 2020
08:13AM EST  The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia   Benzinga
Nov 20, 2020
05:29AM EST  Organogenesis Holdings Director David Burgstahler Reported Purchase of 4,404,162 Shares @ Avg Price of $3.29/Share in a Form 4 Filing Thursday   Benzinga
Nov 19, 2020
04:59PM EST  Organogenesis Holdings 10%+ Owner Wisdom Starr Buys 833,153 @ Avg Price: $3.25   Benzinga
Nov 18, 2020
08:05AM EST  10 Biggest Price Target Changes For Wednesday   Benzinga
04:49AM EST  SVB Leerink Maintains Outperform on Organogenesis Holdings, Raises Price Target to $10   Benzinga
Nov 11, 2020
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
Nov 10, 2020
05:43PM EST  Organogenesis Announces A 17.5M Share Common Stock Offering   Benzinga
11:29AM EST  Organogenesis shares were trading higher after the company reported better-than-expected Q3 EPS and sales results.   Benzinga
09:24AM EST  Credit Suisse Maintains Outperform on Organogenesis Holdings, Raises Price Target to $8   Benzinga
Nov 9, 2020
05:01PM EST  Organogenesis Holdings: Q3 Earnings Insights   Benzinga
04:46PM EST  Organogenesis Holdings Q3 EPS $0.19 Beats $(0.08) Estimate, Sales $100.80M Beat $71.96M Estimate   Benzinga
04:05PM EST  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the three and nine months ended September 30, 2020.   GlobeNewswire Inc
04:13AM EST  Earnings Scheduled For November 9, 2020   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 2, 2020
04:45PM EST  Organogenesis Holdings Announces Research On Its PuraPly AM, Affinity, Apligraf, NuShield And Dermagraft Will Be Presented At 2020 Symposium on Advanced Wound Care (SAWC) Fall Virtual Meeting Nov. 4-6   Benzinga
04:30PM EST  Latest Wound Care Research from Organogenesis Highlighted at SAWC   GlobeNewswire Inc
Oct 15, 2020
02:40PM EDT  Mid-Afternoon Market Update: Nasdaq Down 100 Points; Organogenesis Holdings Shares Jump   Benzinga
02:39PM EDT  Mid-Afternoon Market Update: Dow Down 25 Points; Organogenesis Holdings Shares Jump   Benzinga
12:16PM EDT  Mid-Day Market Update: Crude Oil Down 3%; Cars.com Shares Spike Higher   Benzinga
Oct 14, 2020
05:19PM EDT  13 Stocks Moving In Wednesday's After-Hours Session   Benzinga
04:31PM EDT  Organogenesis Holdings Sees Prelim. Q3 Sales $99M-$100M vs $71.96M Est., Sees FY20 Sales $311M-$314M vs $275.12M Est.   Benzinga
04:30PM EDT  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported preliminary financial results for the three months ended September 30, 2020.   GlobeNewswire Inc
Sep 17, 2020
04:08PM EDT  Organogenesis Holdings Inc. Updates Date And Time Of Presentation At Oppenheimer Fall Healthcare Life Sciences & MedTech Summit To Sept. 21 At 2:30 p.m. ET   Benzinga
04:05PM EDT  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that the date and time of its presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit has been updated.   GlobeNewswire Inc
Sep 3, 2020
04:05PM EDT  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the following upcoming investor conferences:   GlobeNewswire Inc
Aug 24, 2020
04:06PM EDT  Organogenesis Holdings Announces Retirement Of CFO   Benzinga
04:05PM EDT  Organogenesis Holdings Inc. Announces Management Change   GlobeNewswire Inc
Aug 11, 2020
09:34AM EDT  SVB Leerink Maintains Outperform on Organogenesis Holdings, Raises Price Target to $9   Benzinga
Aug 10, 2020
04:35PM EDT  Organogenesis Sees FY20 Sales Guidance $273M-$277M Vs $244.24M Estimates   Benzinga
04:33PM EDT  Organogenesis Holdings Q2 EPS $(0.05) Up From $(0.11) YoY, Sales $69.00M Beat $58.83M Estimate   Benzinga
04:05PM EDT  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the three and six months ended June 30, 2020.   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For August 10, 2020   Benzinga
Jul 23, 2020
04:05PM EDT  Latest Advanced Wound Care Innovations and Research from   GlobeNewswire Inc
Jul 15, 2020
07:32AM EDT  Organogenesis Sees Prelim. Q2 Sales $68M-$68.6M   Benzinga
07:30AM EDT  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported preliminary revenue results for the three months ended June 30, 2020.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC